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Abstract 
 
The efficacy of the novel aquaculture feed ingredient NovacqTM to improve resilience against viral 
infection and mortality in Black Tiger shrimp, Penaeus monodon, was examined. Juvenile 4-6 g 
shrimp were fed either a control diet or treatment diet which included 10% NovacqTM for a 26 d 
conditioning period. Control and treatment shrimp were subsequently each divided into a no 
injection, saline injection or GAV challenge injection sub-treatment with each having four replicate 
tanks of ten shrimp. After injection, shrimp survival in all six treatments was monitored daily over a 
14 d experimental bioassay period. Two of the four replicate tanks for each treatment were pleopod 
sampled for later GAV load quantification at day 0 and 14 of the experimental period (i.e. ‘less 
handling’; survival comparison), whilst the other two replicate tanks were pleopod sampled for later 
GAV load quantification at days 0, 3, 7, 10 and 14 (i.e. ‘more handling’; GAV load comparison). In the 
survival comparison, shrimp fed NovacqTM had significantly higher survival rates (P >0.05) when GAV 
challenged compared to shrimp not fed NovacqTM. Similarly, shrimp fed NovacqTM had marginally 
higher survival rates when injected with saline and compared to their respective control. Shrimp that 
received no injection showed the same survival rates irrespective of diet. In the GAV load 
comparison GAV loads were generally lower in shrimp fed NovacqTM when compared to their 
respective GAV challenge or saline injection controls. Survival and GAV load data indicate that 
NovacqTM improves resilience against viral infection and mortality in Black Tiger shrimp, Penaeus 
monodon. 
 
Introduction 
 
NovacqTM is a novel aquafeed ingredient recently discovered by CSIRO Australia (Patent 
#2008201886). NovacqTM is positioned to revolutionize feed formulation for the global shrimp 
industry conferring in excess of 30% improvement in growth for Black Tiger shrimp, Penaeus 
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monodon and 50% improvement in growth for Pacific White shrimp, Litopennaeus vannamei 
(Glencross et al., 2012b). NovacqTM is a bioactive feed ingredient that has been used to support a 
range of nutritional strategies in shrimp diets including improved growth performance and 
replacement of fish meal, without comprise to performance (Glencross et al., 2012a, 2012b). 
 
Other bioactive substances like crustacean and squid meals are also routinely used in the shrimp 
feed industry (Williams et al., 2005). It has long been recognized that these particular ingredients 
confer biological properties beyond their simple protein and energy supply capacity. While some 
attempt has been made to identify the nature of this bioactive, its use is still largely limited to 
provision through the use of these marine animal ingredients (Williams et al., 2005). However, 
despite evidence of improved growth performance there is little to suggest that these ingredients 
also confer improved ‘fitness’ (Williams et al., 2005). 
 
NovacqTM, although a bioactive ingredient, comprises a product produced from a mixed population 
of marine microorganisms (microalgae and bacteria) that form a microbial biomass and as such are 
not reliant on wild fishery products. Anecdotal observations from earlier trials indicate that when 
fed to shrimp NovacqTM provides heightened fitness (Glencross et al., 2012b). This study therefore 
set out to quantify this fitness in terms of shrimp resilience to viral infection and mortality using an 
established CSIRO Bioassay Challenge System. 
 
Materials and Methods 
 
Feed manufacture 
 
Feed pellets were manufactured that contained either no NovacqTM (control diet) or 10% NovacqTM 
(treatment diet) (Table 1). Each diet was prepared fresh four days before the start of the 
conditioning period. After being removed from storage at -20C, each feed ingredient was 
equilibrated to room temperature before being milled through a  <750 µm rotar mill screen 
(RetschTM ZM200 rotor mill, Retsch Pty Ltd, North Ryde, NSW, Australia), weighed  and mixed in an 
upright planetary mixer (Hobart, Sydney, NSW, Australia). The ingredients were then mixed 
thoroughly with sufficient fresh water added to allow screw-pressing of the mash through a 3 mm 
die. The pelleted feed was then broken into 5 – 10 mm lengths, before being steamed at 95°C for 10 
min prior to being oven dried at 60°C for 24 h, packed in air-tight containers and stored frozen at -
20°C until used. 
 
GAV inoculum preparation 
 
Aliquots from the same Gill-Associated virus (GAV) inoculum preparation as used by Sellars et al. 
(2011) were used in this study. In brief, the GAV inoculum was prepared from Penaeus monodon 
sacrificed when they became moribund following experimental injection of an inoculum stock 
prepared similarly from P. monodon with high-level acute GAV infections. Soft cephalothorax tissues 
of 4 shrimp were diluted in 6 vol shrimp salt solution (SSS) (10 mM HEPES, 450 mM NaCl, 10 mM KCl, 
10 mM EDTA pH 7.2-7.5) that had been 0.22 μm filter sterilized and homogenized on ice using an 
Ultra-Turrax blender until no granular matter was visible. Fine particulate matter in the homogenate 
was removed by centrifugation at 750 x g for 10 min at 4C and then at 15000 rpm for 20 min at 4C 
using a Beckman SW28 rotor. The supernatant was forced through a 0.45 μm filter and 1.0 mL 
aliquots of the inoculum were snap frozen on dry ice and stored at -80C. 
 
Bioassays to define a minimum lethal dose of GAV inoculum  
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As described by Sellars et al. (2011) three bioassays were previously performed to define a minimum 
lethal dose (LD) of this GAV inoculum for selectively bred P. monodon that would reliably result in 
50% accumulated mortality of juveniles by 8 days post-injection (dpi) and 80% accumulated 
mortality by 12 dpi. These bioassays confirmed that the GAV inoculum diluted 1:3 in SSS provided 
the minimum LD reliably generating the specified accumulated mortality levels. However, as the 
present study was performed on unselected P. monodon lines for which CSIRO have anecdotal 
evidence that they are more susceptible to viral infection (CSIRO unpublished information), a GAV 
inoculum dilution of 1:30 in SSS was chosen. The decision to utilise unselected lines in this study was 
two-fold; firstly because selected lines are believed to have specific pathogen tolerance and 
secondly because selected lines have increased feed intake, reduced maintenance demands for 
energy, and improved protein and energy utilization efficiencies that would result in confounding 
complexities when interpreting bioassay results (Glencross et al., 2012a). 
 
Shrimp 
 
Pleopods of first generation unselected P. monodon collected from 11 farm ponds (10 shrimp per 
pond) were pre-screened for the endemic viruses GAV and Mourilyan virus (MoV) using RT-PCR 
(Cowley et al., 2000, 2005). Shrimp (n = 600; ~4-8 g) were collected by cast-netting 12 d later from a 
pond in which neither virus was detected (data not shown) (Pacific Reef Fisheries Pty Ltd., Ayr, 
Queensland, Australia). Shrimp were transported by road and air from Ayr, Queensland to Bribie 
Island, Queensland (~10 h transit) and randomly stocked into four 5-tonne circular bare-bottom 
tanks (150 shrimp in each) for conditioning. 
 
Diet conditioning period 
 
The conditioning tanks received aeration and flow-through seawater at a rate of 1.6 L min-1 
maintaining the water temperature at 28 ± 2oC.  Tanks received alternating 12 h light and 12 h dark 
photoperiods and were covered with a Polygal® lid to reduce light intensity. Two tanks were 
randomly chosen to be fed the control diet whilst the other two tanks were fed the treatment diet 
which included 10% NovacqTM. Shrimp were fed their respective diets for 26 d to excess at 1600 h 
daily and tanks were cleaned by siphoning every 2-3 d. After the 26 d diet conditioning period, tanks 
were drained and shrimp collected for random stocking into the bioassay trial according to 
conditioning treatment. 
 
Experimental bioassay 
 
The experimental bioassay had two diets; control or treatment, followed by three sub-treatments; 
no injection, saline injection or GAV challenge injection. There were four replicate tanks for each of 
the six treatments in total which were randomly assigned to tanks to accommodate any position-
related influences in the facility. Tanks were filled to 80 L with seawater that was aerated, 
maintained at 28 ± 2oC and trickle fed fresh seawater at a rate of ~0.6 L min-1. The tanks had opaque 
white lids and were maintained in a facility providing alternating 12 h light and 12 h dark 
photoperiods. 
 
After collection from corresponding conditioning tanks, 10 randomly chosen shrimp were weighed, 
sex determined, injection performed (described below) and tissue sampled for RNA (described 
below) before being stocked into their allocated tank. Shrimp were continued on their 
corresponding control or treatment diets fed to excess twice each day at 0930 h and 1400 h, and 
waste was siphoned out 3 times per week or as required to maintain water quality. The number of 
shrimp alive in each tank was counted and dead shrimp removed daily at approximately 1400 h. The 
experimental bioassay was performed over a 14 d period. 
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Injection 
In the saline injection treatments 25 µL of SSS was injected into the muscle of the 6th abdominal 
segment using a 100 µL Hamilton glass syringe on day 0 of the experimental bioassay. In the  
GAV challenge treatments GAV inoculum diluted 1:30 in SSS was similarly injected at ~5.0 µL per 1 g 
shrimp weight on day 0 of the experimental bioassay. GAV inoculum volumes adjusted to 
accommodate variations in shrimp weights were 20 µL (4.0-5.0 g), 25 µL (5.0-6.0 g), 30 µL (6.0-7.0 g), 
35 µL (7.0-8.0 g), 40 µL (8.0-9.0 g), 45 µL (9.0-10.0 g), 50 µL (10.0-11.0 g), 55 µL (11.0-12.0 g), 60 µL 
(12.0-13.0 g), 65 µL (13.0-14.0 g), and 70 µL (14.0-15.0 g). 
 
Tissue sampling for RNA 
On day 0 and 14 of the experimental bioassay, a pleopod from every shrimp stocked (day 0) or alive 
(day 14) was sampled for later RNA extraction and GAV load quantification using scissors alcohol 
sterilized between samplings, snap frozen on dry ice and stored at -80°C. Pleopods were sampled in 
an order so as to allow individual identification of shrimp within tanks (i.e. removal of alternating 
pleopods to number shrimp 1 to 10) as previous CSRIO studies have demonstrated pleopod location 
has no correlation with viral load when using the specified species and RT-PCR assays (CSIRO 
unpublished information). Two of the four replicate tanks for each treatment were designated as a 
survival comparison (i.e. ‘less handling’) and not sampled at any other time points. The other two 
replicate tanks for each treatment were designated as a GAV load comparison (i.e. ‘more handling’) 
and on days 3, 7, and 10 in these two tanks of each treatment pleopods were sampled similarly from 
all live shrimp as described. 
 
Real-time PCR quantification of GAV 
 
Shrimp pleopods were homogenized in 600 µL TRIzol reagent (Invitrogen) using 3 glass beads per 
tube and a Savant FastPrep FP120 tissue grinder and total RNA was extracted according to the 
manufacturer’s protocol. RNA was resuspended in 15 µL RNase-free water and before being stored 
at -80C, a 1.5 µL aliquot was examined using a NanoDrop-1000® spectrophotometer to determine 
the RNA concentration and relative purity. cDNA was synthesised in a 10 μL reaction containing 500 
ng total RNA, 50 ng random hexamers and 100 U SuperScriptTM-III reverse transcriptase (Invitrogen) 
according to the manufacturer’s protocol. A TaqMan real-time quantitative (q)RT-PCR test for GAV 
(de la Vega et al., 2004) was performed as described except that 2 µL cDNA (equivalent to 100 ng 
total RNA) was used in a 20 µL reaction prepared using TaqMan® Universal PCR Master Mix (Applied 
Biosystems) and 900 nM each PCR primer, from which 3 x 5 µL aliquots were placed into 3 wells of a 
384-well PCR plate as plate replicates. PCR was performed in an ABI Prism® 9700HT Sequence 
Detection System (Applied Biosystems) using the default thermal cycling conditions. To quantify GAV 
RNA copy numbers accurately, 10-fold dilution series of synthetic GAV RNA of know copy number 
were amplified in the same plates to generate linear regression plots of mean cycle threshold (Ct) 
values vs synthetic RNA copy number. Adjusting for the presence of cDNA prepared to 25 ng total 
RNA in each 5 µL reaction aliquot analyzed, infection loads were expressed as viral RNA copies per 
ng total RNA. 
 
Statistical analysis 
 
Survival of shrimp from the different treatments were analyzed at day 14 using the repeated 
measures ANOVA test (PROC GLM; SAS Institute Software, 1999). Pairwise comparisons 
were made using the Least Significant Difference test (SAS Institute Software, 1999; Kotz 
and Johnson, 1982). 
 
Results 
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Survival comparison 
 
In the survival comparison, shrimp fed NovacqTM had progressively higher survival rates from day 7 
onwards when GAV challenged compared to shrimp not fed NovacqTM (Figure 1). At day 14 shrimp 
fed NovacqTM had 3.5% survival compared to 1% survival for GAV challenged shrimp that were not 
fed NovacqTM (P >0.05). Similarly shrimp fed NovacqTM had marginally higher survival rates when 
injected with saline and compared to their respective control from day 3 onwards (Figure 1). At day 
14 shrimp that received saline injection and that were fed NovacqTM had 9% survival compared to 
8% survival for shrimp that were not fed NovacqTM (P >0.05). Shrimp that received no injection 
showed the same survival rates throughout the duration of the bioassay irrespective of diet (Figure 
1). 
 
GAV load comparison 
 
RT-PCR was used to quantify the indirect impact of NovacqTM on GAV replication levels. A 
representative sub-set of the GAV load comparison shrimp that were either injected with saline or 
GAV inoculum were chosen from each diet treatment for GAV load quantification.  The process for 
selecting these shrimp were as follows; Initially the number of shrimp for each of the respective 
treatments that were alive at day 7 but not beyond, alive at day 10 but not beyond and alive at day 
14 were counted (Table 2). A random sample of shrimp were then selected for GAV quantification 
with more emphasis on selecting shrimp that  had died during this experimental period, resulting in 
selection of 90 pleopod samples from a total of 22 shrimp (Table 1). It is worth noting that caution 
must be taken when interpreting GAV load data from surviving animals in a bioassay challenge trial 
as you are assaying the survivors only. 
 
In the GAV load comparison GAV loads were on average marginally lower for the individuals assayed 
throughout the experimental bioassay in the saline injection comparison when fed NovacqTM (Figure 
2 Ai and Bi). Although less pronounced, GAV loads were also marginally lower for the individuals 
assayed throughout the experimental bioassay in the GAV challenge comparison when fed NovacqTM 
(Figure 2 Aii and Bii).  
 
Discussion  
 
Previous studies have demonstrated that diets containing the novel aquafeed ingredient NovacqTM 
result in significantly improved growth rates of G8 selected and unselected lines of Penaeus 
monodon (Glencross et al., 2012a). Shrimp in this same study were observed to have an overall 
heightened level of ‘fitness’ when fed NovacqTM.  This paper is a first step toward quantifying the 
antiviral ‘fitness’ afforded to shrimp by feeding NovacqTM, which was achieved by performing Gill-
Associated virus (GAV) bioassays on unselected lines of P. monodon shrimp. 
 
Survival comparison 
 
The heightened level of antiviral ‘fitness’ afforded to shrimp by feeding NovacqTM is evident by 
comparison of the survival performance of NovacqTM fed shrimp. Inclusion of NovacqTM in the diet 
resulted in improved shrimp survivals when exposed to the stress of saline injection only and when 
injection stress was combined with GAV challenge. This improved ‘fitness’ or ability to survive as a 
result of stress and viral exposure opens up an opportunity for commercial enterprises to be rearing 
shrimp that are more resilient to environmental extremes (stress) such as extended periods of rain 
or hot weather, and viral outbreaks within ponds. 
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GAV load comparison 
 
A heightened level of antiviral ‘fitness’ afforded to shrimp by feeding NovacqTM is also inferred from 
the GAV load comparison study. GAV loads of NovacqTM fed shrimp were on average lower in 
individual shrimp over the duration of the experimental bioassay when they received the stress of a 
saline in injection only. It has been previously demonstrated that handling stress such as that caused 
by inserting a needle into P. monodon can result in heightened GAV loads of unselected lines (de la 
Vega et al., 2004). Although less pronounced, the same inferred ‘fitness’ measured as generally 
lower GAV loads in individuals throughout the duration of the experimental bioassay, appears 
amongst NovacqTM fed shrimp that received both the handling stress of injection and the GAV 
challenge.  
 
The ability of numerous novel aquafeed ingredients to confer heightened ‘fitness’ in shrimp after 
challenge with viral pathogens have been reported in the literature. As one example, recently the 
herbal extract Nomex® was reported to prevent White Spot Syndrome virus infection in the Pacific 
White shrimp, Litopennaeus vannamei (Dr Dilek Yerlikaya, Soley Biotechnology Institute, USA). 
However, when compared to NovacqTM  there are no other compounds reported in the literature 
that have the combined antiviral, improved growth rate and ability to provide an alternative to fish 
meal in the literature. 
 
In summary, survival and GAV load data in this study confirm that NovacqTM improves resilience 
against viral infection and mortality in Black Tiger shrimp, Penaeus monodon. It is clear that 
NovacqTM is improving the general ‘fitness’ of shrimp and thus acting as an antiviral. Future work 
would benefit from further understanding how NovacqTM stimulates the immune response system in 
shrimp whilst also comparing the antiviral fitness in genetically selected and unselected lines. 
Studies are currently underway to assess the antirviral nature of NovacqTM for L. vannamei when 
challenged with WSSV. Finally, NovacqTM is unlike any other known aquafeed ingredient; providing 
improved shrimp growth, an alternative to fish meal and, as this study shows, resistance to viral 
pathogens. 
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Table 1. Diet formulations and composition as analyzed (% as used). 
 
  Control Treatment 
   Ingredients 
  Fish meal 50.00% 50.00% 
Wheat gluten 5.00% 5.00% 
Wheat flour 41.23% 31.23% 
Lecithin (soy) 1.00% 1.00% 
Fish Oil  2.30% 2.30% 
Novacq 
 
10.00% 
Carophyll Pink 0.05% 0.05% 
Cholesterol 0.10% 0.10% 
Banox E 0.02% 0.02% 
Vitamin C (Stay C) 0.10% 0.10% 
Vitamin premix 0.20% 0.20% 
TOTAL 100.00% 100.00% 
   Diet Composition 
  Dry matter 95.2% 94.7% 
Protein 45.0% 42.7% 
Lipid 7.2% 6.8% 
Ash 9.7% 16.5% 
Carbohydrates 33.3% 28.7% 
Gross Energy 19.5 17.6 
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Table 2. Numbers of shrimp selected for GAV quantification from the GAV load comparison. 
  
Number of shrimp alive at 
day:   
Number of shrimp 
chosen for GAV 
quantification at day:   
Total number of 
pleopods to quantify for 
GAV load at day: 
  
7 but 
not 
beyond 
10 but 
not 
beyond 14   
7 but 
not 
beyond 
10 but 
not 
beyond 14   
7 but 
not 
beyond 
10 but 
not 
beyond 14 
Control Diet saline injection 2 2 11   2 2 2   6 8 10 
Control Diet GAV challenge injection 1 4 2 
 
1 3 2 
 
3 12 10 
Treatment Diet saline injection 1 1 17 
 
1 1 2 
 
3 4 10 
Treatment Diet GAV challenge injection 2 8 2   2 2 2   6 8 10 
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Figure Legends 
 
Figure 1. Mean numbers (± S.D.) of Penaeus monodon shrimp that remained alive over the 14 d 
experimental bioassay for the two survival comparison tank replicates of each treatment group. 
Lines with different superscripts are significantly different at 14 d (P >0.05). Each line represents an 
individual shrimp. 
 
Figure 2. Real-time RT-PCR quantification of Gill-Associated virus (GAV) loads in pleopods of Penaeus 
monodon from the GAV load comparison replicate tanks fed A) Control diet or B) Treatment diet 
with 10% NovacqTM and injected with i) saline or ii) GAV challenge injection. Each line represents an 
individual shrimp over time from which multiple pleopod samples have been taken.  
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